These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39003154)

  • 21. Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.
    Munawar U; Theuersbacher J; Steinhardt MJ; Zhou X; Han S; Nerreter S; Vogt C; Kurian S; Keller T; Regensburger AK; Teufel E; Mersi J; Bittrich M; Seifert F; Haider MS; Rasche L; Hillenkamp J; Einsele H; Kampik D; Kortüm KM; Waldschmidt JM
    Haematologica; 2024 Nov; 109(11):3670-3680. PubMed ID: 38572568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belantamab mafodotin for the treatment of multiple myeloma.
    Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
    Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
    Morè S; Offidani M; Corvatta L; Petrucci MT; Fazio F
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.
    Vaxman I; Abeykoon J; Dispenzieri A; Kumar SK; Buadi F; Lacy MQ; Dingli D; Hwa Y; Fonder A; Hobbs M; Reeder C; Sher T; Hayman S; Kourelis T; Warsame R; Muchtar E; Leung N; Go R; Gonsalves W; Siddiqui M; Kyle RA; Rajkumar SV; Kristen M; Kapoor P; Gertz MA
    Blood Cancer J; 2021 Dec; 11(12):196. PubMed ID: 34876555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Belantamab mafodotin-associated keratopathy-A common and treatment-affecting side effect].
    Augustin VA; Blöck L; Hegenbart U; Auffarth GU; Khoramnia R
    Ophthalmologie; 2023 Apr; 120(4):418-422. PubMed ID: 35925327
    [No Abstract]   [Full Text] [Related]  

  • 26. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
    Collins J; van Noort M; Rathi C; Post TM; Struemper H; Jewell RC; Ferron-Brady G
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1411-1424. PubMed ID: 37465991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin].
    Menardais B; Soethoudt M; Espargillière D; Mouriaux F
    J Fr Ophtalmol; 2021 May; 44(5):766-768. PubMed ID: 33454122
    [No Abstract]   [Full Text] [Related]  

  • 28. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
    Condorelli A; Garibaldi B; Gagliano C; Romano A; Del Fabro V; Parrinello NL; Longo A; Cosentino S; Di Raimondo F; Conticello C
    Acta Haematol; 2024; 147(4):493-498. PubMed ID: 34839282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semi-automation of keratopathy visual acuity grading of corneal events in belantamab mafodotin clinical trials: clinical decision support software.
    Talekar MK; Painter JL; Elizalde MA; Thomas M; Stein HK
    Front Digit Health; 2023; 5():1138453. PubMed ID: 37881364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
    Khwaja J; Bomsztyk J; Atta M; Bygrave C; Forbes A; Durairaj S; Fernandes S; Taylor J; Paterson P; Brearton G; Crawley C; Sheehy O; Brown R; Soutar R; Garg M; Rydzewski A; Jamroziak K; Mahmood S; Wechalekar AD
    Br J Haematol; 2024 May; 204(5):1811-1815. PubMed ID: 38171355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature.
    Lebel E; Vainstein V; Milani P; Palladini G; Shragai T; Lavi N; Magen H; Assayag M; Avivi I; Gatt ME
    Acta Haematol; 2024 Oct; ():1-8. PubMed ID: 39357511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.
    Jaber W; Abdaljalil A; Ali A; Abu Haleeqa M; Mheidly K
    Cureus; 2023 Aug; 15(8):e44433. PubMed ID: 37791224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
    Popat R; Lonial S; Voorhees PM; Esposti SD; Gorsh B; Gupta I; Opalinska J; Sapra S; Piontek T; He Z; Kleinman D; Schaumberg D; Regnault A; Meunier J; Eliason L
    J Adv Pract Oncol; 2023 Sep; 14(6):503-518. PubMed ID: 37808071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and -2 studies.
    Jewell RC; Mills RJ; Farrell C; Visser SAG
    Br J Clin Pharmacol; 2024 Oct; 90(10):2571-2581. PubMed ID: 38924122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Belantamab Mafodotin: First Approval.
    Markham A
    Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.
    Roussel M; Texier N; Nael V; Bitetti J; Paka P; Kerbouche N; Sail L; Colin X; Leleu X
    Eur J Haematol; 2024 Sep; 113(3):310-320. PubMed ID: 38722078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.
    Gavriatopoulou M; Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Spiliopoulou V; Kanellias N; Eleutherakis-Papaiakovou E; Roussou M; Psarros G; Kastritis E; Dimopoulos MA; Terpos E
    Am J Hematol; 2024 Mar; 99(3):502-504. PubMed ID: 38270219
    [No Abstract]   [Full Text] [Related]  

  • 38. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
    Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
    J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.